[Pharmacology of the new oral anticoagulants].

Herz
C-E Dempfle

Abstract

New oral anticoagulants, such as dabigatran, rivaroxaban, apixaban, and edoxaban display pharmacologic and pharmacodynamic data similar to low molecular weight heparins. Peak levels are found 2-4 h after oral ingestion and elimination half-lives are in the range of 7-14 h. The drugs differ primarily concerning renal elimination. Dose adjustment is only performed in patients with impaired renal function, high risk of bleeding and patients with co-medications which influence the metabolism or anticoagulant effect of the drugs. Due to the short half-life, perioperative bridging is not necessary. Currently, no specific antidotes are available: however, assay systems are available for measuring the plasma concentration of dabigatran and rivaroxaban. In emergency cases a normal thrombin time excludes relevant levels of dabigatran, whereas a normal anti-factor Xa assay result excludes relevant levels of factor Xa inhibitors.The new anticoagulants are being used for prophylaxis of venous thrombosis in elective hip and knee surgery, as well as for treatment of venous thrombosis and for prevention of stroke and systemic embolism in patients with atrial fibrillation. Additional indications are to follow. Dabigatran is given at a dose of 1...Continue Reading

References

Apr 19, 2002·Journal of Medicinal Chemistry·Norbert H HauelWolfgang Wienen
Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·E PerzbornA Straub
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Dagmar KubitzaGeorg Wensing
Nov 15, 2006·British Journal of Clinical Pharmacology·Dagmar KubitzaMichael Zuehlsdorf
Jun 29, 2007·International Journal of Clinical Pharmacology and Therapeutics·W MueckM Zuehlsdorf
Aug 22, 2008·Current Medical Research and Opinion·Dagmar KubitzaWolfgang Mueck
Oct 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nirmala RaghavanDonglu Zhang
Apr 8, 2009·Thrombosis and Haemostasis·Xiaosui JiangPancras C Wong
Aug 22, 2009·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Joachim Stangier, Andreas Clemens
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Nov 27, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lifei WangScott J Grossman
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
Jul 21, 2010·Cerebrovascular Diseases·Carl-Erik H Dempfle, Michael G Hennerici
Sep 2, 2010·Thrombosis and Haemostasis·Meyer Michel SamamaFrançois Depasse
Sep 17, 2010·Therapeutic Drug Monitoring·Edelgard Lindhoff-LastTheodore E Spiro
Oct 16, 2010·Journal of Thrombosis and Haemostasis : JTH·A HillarpT L Lindahl
Oct 16, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Mihai GheorghiadePaul Burton
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Dec 22, 2010·Journal of Enzyme Inhibition and Medicinal Chemistry·Joseph M LuettgenAlan R Rendina
Feb 12, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN AVERROES Steering Committee and Investigators
Mar 2, 2011·Journal of Thrombosis and Thrombolysis·Edith NutescuErika Hellenbart
Jun 7, 2011·The American Journal of Medicine·Christina E DeRemerRobert A Sorrentino
Jun 30, 2011·The Annals of Pharmacotherapy·Lawrence Baruch, Olga Sherman
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 25, 2011·Drugs·A John Camm, Henri Bounameaux
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Dec 22, 2011·Thrombosis and Haemostasis·Meyer Michel SamamaUNKNOWN Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories

❮ Previous
Next ❯

Citations

Dec 7, 2013·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Lawrence E GreitenHartzell V Schaff
Apr 26, 2017·Archives of Orthopaedic and Trauma Surgery·Adriane MayerBernd Fink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.